A köpenysejtes lymphoma terápiája

Translated title of the contribution: Therapy of mantle cell lymphoma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) belongs to the so-called peripheral (differentiated) B cell non-Hodgkin lymphomas. In spite of that, it runs an aggressive course; quick progression and most cases are diagnosed in advanced stages. On the other hand, chemotherapy and immunochemotherapy (in contrast with other aggressive lymphomas) are not able to show any curative potential. However, combined efforts of first line antiCD20 based intensified immunochemotherapy along with high dose therapy (preferably irradiation based conditioning regimens) and autologous transplant consolidation of first complete remission achieves major breakthrough and prolongation of life expectancies of 7-10 years instead of the 2.5-3 years average survival of the traditional chemotherapeutic approach. A lot of new agents (i.e. the FDA approved MCL indication of bortezomib, temsirolimus, thalidomide, etc.) are or should be available for the refractory or relapsed patients. This short review summarizes the most important advances of MCL therapy and provides an updated therapeutic recommendation.

Original languageHungarian
Pages (from-to)2253-2257
Number of pages5
JournalOrvosi Hetilap
Volume150
Issue number50
DOIs
Publication statusPublished - Dec 1 2009

Fingerprint

Mantle-Cell Lymphoma
Life Support Care
Thalidomide
Autografts
B-Cell Lymphoma
Cell- and Tissue-Based Therapy
Life Expectancy
Non-Hodgkin's Lymphoma
Lymphoma
Therapeutics
Drug Therapy
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A köpenysejtes lymphoma terápiája. / Udvardy, M.

In: Orvosi Hetilap, Vol. 150, No. 50, 01.12.2009, p. 2253-2257.

Research output: Contribution to journalArticle

Udvardy, M. / A köpenysejtes lymphoma terápiája. In: Orvosi Hetilap. 2009 ; Vol. 150, No. 50. pp. 2253-2257.
@article{150653f8b5954dceb449fa8714625666,
title = "A k{\"o}penysejtes lymphoma ter{\'a}pi{\'a}ja",
abstract = "Mantle cell lymphoma (MCL) belongs to the so-called peripheral (differentiated) B cell non-Hodgkin lymphomas. In spite of that, it runs an aggressive course; quick progression and most cases are diagnosed in advanced stages. On the other hand, chemotherapy and immunochemotherapy (in contrast with other aggressive lymphomas) are not able to show any curative potential. However, combined efforts of first line antiCD20 based intensified immunochemotherapy along with high dose therapy (preferably irradiation based conditioning regimens) and autologous transplant consolidation of first complete remission achieves major breakthrough and prolongation of life expectancies of 7-10 years instead of the 2.5-3 years average survival of the traditional chemotherapeutic approach. A lot of new agents (i.e. the FDA approved MCL indication of bortezomib, temsirolimus, thalidomide, etc.) are or should be available for the refractory or relapsed patients. This short review summarizes the most important advances of MCL therapy and provides an updated therapeutic recommendation.",
keywords = "Autologous transplantation, Immunochemotherapy, Mantle cell lymphoma, Rituximab",
author = "M. Udvardy",
year = "2009",
month = "12",
day = "1",
doi = "10.1556/OH.2009.28763",
language = "Hungarian",
volume = "150",
pages = "2253--2257",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "50",

}

TY - JOUR

T1 - A köpenysejtes lymphoma terápiája

AU - Udvardy, M.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Mantle cell lymphoma (MCL) belongs to the so-called peripheral (differentiated) B cell non-Hodgkin lymphomas. In spite of that, it runs an aggressive course; quick progression and most cases are diagnosed in advanced stages. On the other hand, chemotherapy and immunochemotherapy (in contrast with other aggressive lymphomas) are not able to show any curative potential. However, combined efforts of first line antiCD20 based intensified immunochemotherapy along with high dose therapy (preferably irradiation based conditioning regimens) and autologous transplant consolidation of first complete remission achieves major breakthrough and prolongation of life expectancies of 7-10 years instead of the 2.5-3 years average survival of the traditional chemotherapeutic approach. A lot of new agents (i.e. the FDA approved MCL indication of bortezomib, temsirolimus, thalidomide, etc.) are or should be available for the refractory or relapsed patients. This short review summarizes the most important advances of MCL therapy and provides an updated therapeutic recommendation.

AB - Mantle cell lymphoma (MCL) belongs to the so-called peripheral (differentiated) B cell non-Hodgkin lymphomas. In spite of that, it runs an aggressive course; quick progression and most cases are diagnosed in advanced stages. On the other hand, chemotherapy and immunochemotherapy (in contrast with other aggressive lymphomas) are not able to show any curative potential. However, combined efforts of first line antiCD20 based intensified immunochemotherapy along with high dose therapy (preferably irradiation based conditioning regimens) and autologous transplant consolidation of first complete remission achieves major breakthrough and prolongation of life expectancies of 7-10 years instead of the 2.5-3 years average survival of the traditional chemotherapeutic approach. A lot of new agents (i.e. the FDA approved MCL indication of bortezomib, temsirolimus, thalidomide, etc.) are or should be available for the refractory or relapsed patients. This short review summarizes the most important advances of MCL therapy and provides an updated therapeutic recommendation.

KW - Autologous transplantation

KW - Immunochemotherapy

KW - Mantle cell lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=71549139738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71549139738&partnerID=8YFLogxK

U2 - 10.1556/OH.2009.28763

DO - 10.1556/OH.2009.28763

M3 - Article

C2 - 19951856

AN - SCOPUS:71549139738

VL - 150

SP - 2253

EP - 2257

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 50

ER -